scholarly journals PT578. Endothelial-monocyte-activating polypeptide-2 (EMAP-2) may be a novel treatment target of Alzheimer’s disease

2016 ◽  
Vol 19 (Suppl_1) ◽  
pp. 13-13
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Treatment Target ◽  
Novel Treatment

scholarly journals Nutraceutical Approaches of Autophagy and Neuroinflammation in Alzheimer’s Disease: A Systematic Review

Molecules ◽  
2020 ◽  
Vol 25 (24) ◽  
pp. 6018
Author(s):  
Reinhard Gruendler ◽  
Berit Hippe ◽  
Vesna Sendula Jengic ◽  
Borut Peterlin ◽  
Alexander G. Haslberger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preventive Measures ◽  
Memory Loss ◽  
Epigallocatechin Gallate ◽  
Clinical Impact ◽  
Food Sources ◽  
Severe Dementia ◽  
Novel Treatment ◽  
Positive Outlook

Aging and the emergence of age-associated illnesses are one of the major challenges of our present society. Alzheimer’s disease (AD) is closely associated with aging and is defined by increasing memory loss and severe dementia. Currently, there are no therapy options available that halt AD progression. This work investigates three hallmarks of the disease (autophagy, neuroinflammation, and senescence) and systematically analyzes if there is a beneficial effect from three substances derived from food sources, the so called “nutraceuticals” epigallocatechin gallate, fisetin, and spermidine, on these hallmarks. The results imply a positive outlook for the reviewed substances to qualify as a novel treatment option for AD. A combination of nutraceutical substances and other preventive measures could have significant clinical impact in a multi-layered therapy approach to counter AD.

scholarly journals Apathy as a treatment target in Alzheimer's disease: implications for clinical trials

2021 ◽  
Author(s):  
Moyra E. Mortby ◽  
Lawrence Adler ◽  
Luis Agüera-Ortiz ◽  
Daniel R. Bateman ◽  
Henry Brodaty ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Treatment Target

Lithium: a novel treatment for Alzheimer's disease?

2007 ◽  
Vol 6 (4) ◽  
pp. 375-383 ◽  
Author(s):  
Jin Zhong ◽  
Wei-Hua Lee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Novel Treatment

scholarly journals The role of epigenetic modifications in Alzheimer’s disease

2020 ◽  
Vol 9 (1) ◽  
pp. 294
Author(s):  
Shierly . ◽  
Chandra Wirawan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Manifestations ◽  
Epigenetic Modifications ◽  
Novel Treatment ◽  
Amyloid Aβ ◽  
Memory Deterioration ◽  
Primary Risk Factor ◽  
Cognitive Disturbance

Aging is the primary risk factor for various neurodegenerative diseases, including Alzheimer’s disease (AD), which is the most frequent form of Dementia. AD is progressive neurodegenerative disease with abnormal protein production, inflammation and memory deterioration. The main clinical manifestations of this illness are cognitive disturbance and memory deficit. Abnormal of beta-amyloid (Aβ), neurofibrillary tangles (NFTs) and tau deposition are the most common findings pathology in this disease. Recent studies indicate that epigenetic modifications strongly correlate in developing these pathology and disease progression. The hallmarks of epigenetic modifications are DNA (deoxyribonucleic acid) methylation, histone modifications, chromatin remodeling and ncRNA (non-coding ribonucleic acid) expressions. This review aims to explain the potential mechanisms of epigenetic modifications associate with this disease. The general conclusion of this review is that epigenetic modifications play an ultimate role in AD and there are potential biomarkers of AD and future novel treatment of AD based on epigenetics.

Sign in / Sign up

Export Citation Format

Share Document